Original Article
Dapsone-Pyrimethamine Compared with Aerosolized Pentamidine as Primary Prophylaxis against Pneumocystis carinii Pneumonia and Toxoplasmosis in HIV Infection
N Engl J Med 1993; 328:1514-1520May 27, 1993
- Abstract
Background
Pneumocystis carinii pneumonia and toxoplasmic encephalitis are frequent life-threatening opportunistic infections in patients with human immunodeficiency virus (HIV) infection. Primary prophylaxis against P. carinii pneumonia is now common, but there are few data on regimens for primary prophylaxis against toxoplasmosis.
Methods
We conducted a randomized trial that compared two prophylactic regimens: dapsone (50 mg per day) plus pyrimethamine (50 mg per week) was compared with aerosolized pentamidine (300 mg per month). The patients had symptomatic HIV infection, no history of P. carinii pneumonia or symptomatic toxoplasmosis, and CD4+ counts below 200 per cubic millimeter (0.2 × 109 per liter).
Results
In an intention-to-treat analysis, after a median follow-up of 539 days P. carinii pneumonia developed in 10 patients in each group, whereas toxoplasmosis developed in 32 of 176 patients in the pentamidine group and 19 of 173 patients in the dapsone-pyrimethamine group. Those assigned to pentamidine had a risk of P. carinii pneumonia that was similar to the risk in those assigned to dapsone-pyrimethamine (adjusted relative risk, 1.13; 95 percent confidence interval, 0.44 to 2.92; P = 0.79), but a higher risk of toxoplasmosis (adjusted relative risk, 1.81; 95 percent confidence interval, 1.12 to 2.94; P = 0.02). Among the 262 patients with serologic evidence of past exposure to Toxoplasma gondii, the relative risk of symptomatic toxoplasmosis was 2.37 times higher in those assigned to pentamidine (95 percent confidence interval, 1.3 to 4.4; P = 0.006). More patients discontinued dapsone-pyrimethamine than pentamidine because of toxicity (42 vs. 3; P<0.001). Survival was similar in the two groups.
Conclusions
For primary prevention of P. carinii pneumonia, dapsone-pyrimethamine is as effective, though not as well tolerated, as aerosolized pentamidine. Dapsone-pyrimethamine also prevents first episodes of toxoplasmosis.
Media in This Article
Figure 1
Cumulative Proportion of Patients Remaining Free of Confirmed or Presumptive P. carinii Pneumonia (PCP) in Each Study Group.Figure 2
Cumulative Proportion of Patients Remaining Free of Opportunistic Toxoplasmosis in Each Study Group.Article Activity
- Article
Pneumocystis carinii pneumonia has been the most frequent life-threatening opportunistic infection in patients infected with the human immunodeficiency virus (HIV),1,2 but its incidence has fallen with the use of primary prophylaxis in persons with CD4+ T-lymphocyte counts below 200 per cubic millimeter (0.2 × 109 per liter.)3 Oral trimethoprim-sulfamethoxazole4-6 and aerosolized pentamidine7-11 have demonstrated efficacy and are the regimens most frequently used to prevent both first episodes and relapses of P. carinii pneumonia. Two recent trials demonstrated better efficacy but poorer tolerance of trimethoprim-sulfamethoxazole as compared with aerosolized pentamidine for primary12 and secondary13 prophylaxis. Dapsone is effective against P. carinii pneumonia in the animal model14 and, when combined with trimethoprim, for the treatment of the disease in humans15. It has mainly been evaluated as prophylaxis alone or in combination with pyrimethamine in uncontrolled studies16-21 and in two trials comparing it with trimethoprim-sulfamethoxazole22 and aerosolized pentamidine23.
In contrast to the declining incidence of P. carinii pneumonia, the incidence of toxoplasmic encephalitis, the most frequent presentation of opportunistic toxoplasmosis, is increasing markedly24,25. The development of opportunistic toxoplasmosis is mainly thought to be due to the reactivation of latent infection; this life-threatening disease is expected to develop in about one third of HIV-infected persons with antibodies to Toxoplasma gondii26. The highest incidence of toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome (AIDS) has been reported in Europe,25,27 where the seroprevalence of T. gondii in adults may exceed 70 percent28. In France, for example, it is the first AIDS-defining manifestation in 23 percent of patients25. Because aerosolized pentamidine has no activity against T. gondii and the efficacy of trimethoprim-sulfamethoxazole remains to be proved, there is a great need for an effective prophylaxis. The drug combinations used to treat toxoplasmosis (pyrimethamine-sulfadiazine and pyrimethamine-clindamycin) are poor candidates for primary prophylaxis because of their side effects29,30. Sulfone compounds inhibit the T. gondii dihydropteroate synthetase,31 and dapsone is synergistic with pyrimethamine both in vitro and in animal models32,33.
In a randomized trial, we compared aerosolized pentamidine with the dapsone-pyrimethamine combination for the primary prevention of P. carinii pneumonia and assessed the value of dapsone-pyrimethamine as primary prophylaxis against opportunistic toxoplasmosis.
Methods
Study Population
The study design was approved by the ethics committee of the Hopital Bichat-Claude Bernard, Paris, and all participants gave written informed consent before enrollment. The participants were adults with HIV infection classified as belonging to group IV according to the definition of the Centers for Disease Control and Prevention (CDC)34; they had no history of P. carinii pneumonia or toxoplasmic encephalitis, had not received prophylaxis against these diseases, and had CD4+ T-lymphocyte counts below 200 per cubic millimeter. Patients receiving zidovudine were eligible for the study. The criteria for eligibility also included a hemoglobin level of more than 10 g per deciliter, a total neutrophil count of more than 750 per cubic millimeter (0.75 × 109 per liter), and serum aspartate and alanine aminotransferase levels less than 10 times the upper limit of normal. The criteria for exclusion were pregnancy, asthma requiring long-term treatment, a history of adverse reactions to sulfonamides or sulfones, glucose-6-phosphate dehydrogenase deficiency, ischemic cardiomyopathy, and a serum creatinine concentration greater than 2.26 mg per deciliter (200 μmol per liter). In addition, patients who had a history of central nervous system disease or diseases requiring maintenance therapy with drugs with activity against P. carinii or T. gondii or who had contraindications to the use of aerosolized pentamidine (active pulmonary tuberculosis or pulmonary Kaposi's sarcoma) were not eligible. Other forms of prophylaxis against P. carinii pneumonia or toxoplasmosis were not allowed.
Study Design
This open, randomized, controlled study was conducted in 16 French centers. Block randomization using sealed envelopes was carried out at each center to ensure that three of every six consecutive patients would be assigned to treatment with pentamidine and three to treatment with dapsone-pyrimethamine. The randomization was stratified according to the patients' clinical status. Stratum A included patients with AIDS-related complex who had not received antiretroviral therapy or who had received it for less than six months. Stratum B included patients with AIDS, regardless of previous zidovudine therapy, and patients with AIDS-related complex who had received zidovudine for more than six months.
Treatment according to the protocol was started within a month of randomization and was planned to last for two years. Aerosolized pentamidine isethionate (Pentacarinat, Laboratoires Roger Bellon, Neuilly-sur-Seine, France) was delivered through a Respirgard II nebulizer (Marquest, Englewood, N.J.) at a dosage of 300 mg once a month (±3 days) under the supervision of a nurse. The administration of a bronchodilator before the inhalations was recommended.
Dapsone (50 mg once a day; Laboratoires Specia, Paris), pyrimethamine (50 mg once a week; Malocide, Laboratoires Specia), and folinic acid (25 mg once a week; Laboratoires Roger Bellon) were dispensed in blister packs.
Evaluation of the Patients
The participants underwent a thorough clinical examination every three months. Laboratory tests, including a differential blood count and CD4+ T-lymphocyte count, were performed at entry and every three months. Serologic tests for T. gondii were performed every six months when the results of such testing were negative before the patient's inclusion in the study. In addition, the reticulocyte count, methemoglobin level, and serum haptoglobin level were monitored every three months in the patients receiving dapsone-pyrimethamine.
Clinical End Points
Episodes of P. carinii pneumonia were defined by the onset of pneumonia clinically and radiologically consistent with acute P. carinii pneumonia, even in the absence of microscopical confirmation, if it responded to antipneumocystis therapy. Confirmed cases of P. carinii pneumonia were those in which P. carinii was detected in induced sputum, bronchoalveolar-lavage fluid, or lung tissue.
Toxoplasmic encephalitis was diagnosed if T. gondii tachyzoites or cysts were identified in brain tissue obtained by biopsy or autopsy or if a ring-enhancing lesion or lesions were found on computed tomography or magnetic resonance imaging. Less characteristic radiologic abnormalities were also considered diagnostic for toxoplasmic encephalitis if there was improvement during specific treatment (i.e., pyrimethamine plus either sulfadiazine or clindamycin). Histologic proof was not required, because brain biopsy is not routinely indicated in this setting. In the light of contemporary observations,35-37 the protocol was amended during the enrollment period to include extracerebral toxoplasmosis as a clinical end point. Extracerebral toxoplasmosis was diagnosed when there were characteristic funduscopic features responsive to specific therapy (retinal toxoplasmosis) or when tachyzoites or cysts were identified in bronchoalveolar fluid or lung tissue (pulmonary toxoplasmosis).
Deaths during short-term treatment of P. carinii pneumonia or toxoplasmosis were considered to be due to these diseases. All critical events involving the occurrence of P. carinii pneumonia, toxoplasmosis, or death were reviewed by a Critical Events Committee that was unaware of the patients' treatment assignments.
Statistical Analysis
The enrollment target of 280 patients was increased to 360 patients in September 1990 on the basis of recent data on the incidence of opportunistic infections in zidovudine-treated patients in France38.
The statistical analyses were based on the intention-to-treat principle. Only patients who never started the planned prophylactic regimen were excluded from this analysis. The results were analyzed by the chi-square test or Fisher's exact test in the case of categorical variables and by one-way and two-way analyses of variance and Student's t-test in the case of continuous variables. The time-to-event distributions were plotted with Kaplan-Meier curves and compared by a log-rank test. Cox proportional-hazards regression was used to estimate the difference between the two regimens after adjustment for the following base-line covariates39: study center, age, sex, risk factors for HIV infection, stratum of randomization, HIV disease stage according to the CDC classification, history of herpes zoster, and CD4+ T-lymphocyte count. In addition, the results of T. gondii serologic testing obtained before enrollment in the study were included in the model for comparison of the occurrence of toxoplasmosis in the two study groups. All P values were two-tailed, and P values of 0.05 or less were considered to indicate statistical significance.
Given the numerous critical events observed, the Data and Safety Monitoring Committee requested an interim analysis in October 1991. On the basis of the rules of O'Brien and Fleming,40 discontinuation of the trial on December 18, 1991, was recommended. The analysis presented here is based on data obtained up to December 19, 1991.
Results
Study Population
From July 1989 through November 1990, 362 patients were randomized. Thirteen of these patients (four in the pentamidine group and nine in the dapsone-pyrimethamine group) did not receive their assigned regimens within a month of randomization and were not included in the analysis. Among the 349 who could be evaluated, 176 were randomly assigned to pentamidine, and 173 to dapsone-pyrimethamine; 256 patients were included in stratum A, and 93 in stratum B. The two study groups were well matched with respect to base-line characteristics (Table 1Table 1
Selected Base-Line Characteristics of the Study Patients.), the only significant difference being one concerning a history of herpes zoster (8 percent in the pentamidine group vs. 16 percent in the dapsone-pyrimethamine group; P = 0.03).Outcome
The median follow-up was 539 days and did not differ significantly between the two groups. Twenty episodes of P. carinii pneumonia, 51 episodes of toxoplasmosis, and 86 deaths occurred during the study. One hundred thirty-eight patients completed the study -- i.e., they continued to receive the assigned therapy and did not reach an end point. Eight patients in the pentamidine group and four in the dapsone-pyrimethamine group were lost to follow-up at least six months before the end of the trial, and therefore data on these patients were censored at the last visit. One hundred thirty patients discontinued the assigned treatment because of drug intolerance, violations of protocol, or other reasons, but they were monitored nonetheless.
The mean (±SE) daily dosage of zidovudine tended to be lower in the dapsone-pyrimethamine group than in the pentamidine group: 413 ±25 and 475 ±21 mg per day, respectively (P = 0.06). Twenty-one patients in the dapsone-pyrimethamine group and 25 patients in the pentamidine group were switched from zidovudine to didanosine.
Occurrence of P. carinii Pneumonia
P. carinii pneumonia developed in 10 of the 176 patients in the pentamidine group (5.7 percent) and in 10 of the 173 patients in the dapsone-pyrimethamine group (5.8 percent), corresponding to rates of 0.32 and 0.33 cases, respectively, per 100 patient-months. The cumulative proportion of patients remaining free of P. carinii pneumonia is shown in Figure 1Figure 1
Cumulative Proportion of Patients Remaining Free of Confirmed or Presumptive P. carinii Pneumonia (PCP) in Each Study Group.. One patient in the pentamidine group had an upper-lobe localization of the pneumonia. Seventeen of the 20 episodes of P. carinii pneumonia were confirmed microscopically. In the dapsone-pyrimethamine group, two patients in whom the pneumonia developed were receiving didanosine concomitantly. In the Cox proportional-hazards regression model, the risk of P. carinii pneumonia in the participants assigned to pentamidine was 1.13 times that in the participants assigned to dapsone-pyrimethamine (95 percent confidence interval, 0.44 to 2.92; P = 0.79). No cases of P. carinii pneumonia occurred after an episode of toxoplasmosis. One death in the dapsone-pyrimethamine group was due to P. carinii pneumonia.Occurrence of Toxoplasmosis
Among the 51 patients with toxoplasmosis, the localization was cerebral in 46, ocular in 4, and pulmonary in 1. Toxoplasmosis developed in 32 of the 176 patients in the pentamidine group (18.2 percent) as compared with 19 of the 173 patients in the dapsone-pyrimethamine group (11.0 percent), corresponding to rates of 1.08 and 0.63 cases, respectively, per 100 patient-months (Figure 2Figure 2
Cumulative Proportion of Patients Remaining Free of Opportunistic Toxoplasmosis in Each Study Group.). The adjusted risk of toxoplasmosis in the participants assigned to aerosolized pentamidine was 1.81 times that in the participants assigned to dapsone-pyrimethamine (95 percent confidence interval, 1.12 to 2.94; P = 0.02). All but one of the patients in whom toxoplasmosis developed had serologic evidence of past exposure to T. gondii at the time of inclusion in the study. The remaining patient had seroconverted by the time toxoplasmosis developed. In the subgroup of patients who were seropositive for T. gondii at enrollment, the adjusted relative risk of toxoplasmosis in the pentamidine group was 2.37 times that in the dapsone-pyrimethamine group (95 percent confidence interval, 1.3 to 4.4; P = 0.006).During the time in which the patients were receiving the assigned regimen, toxoplasmosis developed in 28 of 176 patients in the pentamidine group and in 5 of 173 patients in the dapsone-pyrimethamine group, corresponding to rates of 1.13 and 0.25 cases per 100 patient-months, respectively. The adjusted relative risk of toxoplasmosis in the participants assigned to pentamidine was 5.6 times that in the participants assigned to dapsone-pyrimethamine (95 percent confidence interval, 2.1 to 15; P<0.001). In 8 of the 42 patients who discontinued dapsone-pyrimethamine because of intolerance, toxoplasmosis subsequently developed after a mean of 257 ±59 days. Seven of the eight patients were receiving aerosolized pentamidine, and the eighth was receiving no prophylaxis.
In the pentamidine group, the independent predictive factors for toxoplasmosis were a positive serologic test for T. gondii (P<0.001), lower CD4+ T-lymphocyte count (P = 0.03), and lower daily dose of zidovudine during the trial (P = 0.02). Four patients in each study group died of toxoplasmosis. In each group, one case of toxoplasmosis occurred in a patient in whom P. carinii pneumonia had already developed.
Survival
Forty-one and 45 patients died in the pentamidine and dapsone-pyrimethamine groups, respectively (relative risk, 0.74; 95 percent confidence interval, 0.47 to 1.16; P = 0.20). The respective median survival times were 576 and 581 days. Among the 86 deaths, the primary cause of death was P. carinii pneumonia or toxoplasmosis in 9, another AIDS-related disease in 72 (including neoplasia in 18), and a disease not related to AIDS in 5.
Side Effects
Table 2Table 2
Adverse Reactions in the Study Patients. shows the observed adverse reactions and those causing interruptions of prophylaxis in the two study groups. The dose of dapsone-pyrimethamine was reduced by half or temporarily discontinued in 14 and 4 patients, respectively. Interruptions of prophylaxis because of drug-related side effects were significantly more frequent in the dapsone-pyrimethamine group (42 of 173) than in the pentamidine group (3 of 176) (P<0.001 by the log-rank test). The probability of discontinuing oral prophylaxis was highest during the first three months (Figure 3Figure 3
Cumulative Proportion of Patients in Each Study Group Who Did Not Discontinue Their Assigned Prophylaxis Because of Intolerance.). Only the neutrophil count obtained before enrollment in the study was predictive of the discontinuation of dapsone-pyrimethamine. The relative risk of discontinuing this treatment in patients with a neutrophil count below 2000 per cubic millimeter (2 × 109 per liter) was 1.92 (95 percent confidence interval, 1.04 to 3.54; P = 0.04) as compared with patients who had a higher neutrophil count. No deaths related to the prophylaxis were reported.There was a significant decrease in the hemoglobin level and the white-cell, neutrophil, and CD4+ T-lymphocyte counts in both groups. The decrease in the hemoglobin level was significantly greater in the dapsone-pyrimethamine group than in the pentamidine group (from 13.0 ±0.1 to 11.7 ±0.2 vs. 13.0 ±0.1 to 12.4 ±0.1 g per deciliter; P<0.001). In 117 patients in the dapsone-pyrimethamine group for whom the information was available, the serum haptoglobin level decreased from 222 ±13 to 131 ±11 mg per deciliter (P<0.001) after 14.2 ±0.6 months. There was no significant change in the reticulocyte count or the methemoglobin level.
Discussion
This open, randomized trial found aerosolized pentamidine and dapsone-pyrimethamine to be equally effective in preventing first episodes of P. carinii pneumonia. Dapsone-pyrimethamine drastically reduced the incidence of opportunistic toxoplasmosis, although it was less well tolerated than aerosolized pentamidine.
Prevention of P. carinii Pneumonia
From previous cohort data25,41 one can estimate a two-year incidence of P. carinii pneumonia in this population of about 40 percent in the absence of prophylaxis. The one-year incidence in the placebo group of a controlled trial of aerosolized pentamidine for primary prevention of P. carinii pneumonia was 27 percent11. The high efficacy of pentamidine in our trial contrasts with the relatively lower success rate found in a comparative trial with trimethoprim-sulfamethoxazole,13 possibly because that trial involved secondary prophylaxis in patients who were more severely immunosuppressed and in whom deposition of the drug in the lung may be altered. In other trials of pentamidine for primary prophylaxis, the one-year incidence of P. carinii pneumonia was 8.6 percent11 and 11 percent,12 as compared with 4.7 percent in our trial. Tolerance of aerosolized pentamidine and compliance with this treatment were both good in the present trial, as in others7-13.
The combination with pyrimethamine allowed the daily dosage of dapsone to be reduced; the incidence of side effects was thus lower than in a previous trial, in which 42 percent of the patients withdrew because of drug intolerance22. Discontinuation of prophylaxis was significantly more frequent in the dapsone-pyrimethamine group than in the pentamidine group. Side effects were mild and resolved after drug withdrawal. Even at the lower dosage of dapsone, however, we did observe anemia due at least in part to chronic hemolysis, a well-known effect of the drug. Agranulocytosis reported with dapsone alone42 or in combination with pyrimethamine43 did not occur. One patient discontinued the treatment because of asymptomatic methemoglobinemia.
As first-line primary prophylaxis against P. carinii pneumonia, the two test regimens did not differ in efficacy, but a number of drawbacks have been reported with aerosolized pentamidine, including treatment failures,7-13 localization of the pneumonia to the upper lungs,44 disseminated P. carinii pneumonia,45 and environmental drug contamination and dissemination of respiratory pathogens46. Despite a higher incidence of side effects with dapsone-pyrimethamine, this combination appears to be an attractive alternative. The risk of severe hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency, although this condition is rare in non-Mediterranean whites, may require screening before dapsone is used. Pharmacologic interactions with rifampin47 have been reported, as well as reduced absorption of dapsone when it is given concomitantly with buffered drugs, such as didanosine48.
Trimethoprim-sulfamethoxazole, which appeared to be more effective than aerosolized pentamidine in two recent trials,12,13 has been officially recommended in the United States as first-line prophylaxis against P. carinii pneumonia49. A comparative trial with dapsone-pyrimethamine is needed to determine which regimen has the best risk-benefit ratio.
Prevention of Toxoplasmosis
Dapsone-pyrimethamine reduced the incidence of toxoplasmosis, for which primary prophylaxis has not been recommended in HIV-infected patients50. In the pentamidine group, the two-year actuarial incidence of toxoplasmosis (24.3 percent) was consistent with previous reports37.
The decision to discontinue the trial at the interim analysis was prompted by the significant protective effect of dapsone-pyrimethamine against toxoplasmosis (P = 0.018 by the log-rank test; adjusted relative risk, 2.33; 95 percent confidence interval, 1.19 to 4.55; P = 0.01). At the final analysis, this effect was confirmed by the low incidence of toxoplasmosis among the patients who continued to take this combination of drugs as prophylaxis.
Primary prophylaxis against opportunistic toxoplasmosis in HIV-infected patients is warranted because of the serious morbidity and sequelae of this life-threatening disease29. In the subgroup of patients seropositive for T. gondii and with CD4+ T-lymphocyte counts below 100 per cubic millimeter (0.1 × 109 per liter) in the pentamidine group, the probability of toxoplasmosis after 18 months was 40 percent, according to multivariate analysis (data not shown).
Recent trials and observational studies suggest that trimethoprim-sulfamethoxazole, primarily prescribed for prophylaxis against P. carinii pneumonia, may also reduce the risk of toxoplasmosis13,51. Further studies with this combination are warranted.
This trial demonstrates the feasibility of targeting more than one opportunistic pathogen in HIV-infected patients. Because the trial included two opportunistic infections as end points, potential bias due to the cross-reactivity of curative therapy must be taken into account. If only the first event (P. carinii pneumonia or toxoplasmosis) was considered, the conclusions were the same (data not shown). However, we cannot exclude the possibility in the intention-to-treat analysis that in the pentamidine group the risk of P. carinii pneumonia was reduced by the higher incidence of toxoplasmosis, which led to short-term and maintenance therapy with activity against P. carinii52.
Although this trial was not specifically designed to evaluate mortality, there was no advantage in terms of survival for the dapsone-pyrimethamine group in relation to the pentamidine group, despite the efficacy of the drug combination in preventing toxoplasmosis. Interestingly, previous trials of primary or secondary prophylaxis against opportunistic infections (P. carinii pneumonia and cryptococcal meningitis) in HIV-infected patients have failed to demonstrate a survival benefit despite remarkable preventive efficacy7,8,53.
The data presented here provide a basis for the primary prevention of two major life-threatening opportunistic infections in HIV-infected patients with low CD4+ T-lymphocyte counts. When the prevention of P. carinii pneumonia alone is required, aerosolized pentamidine is effective and well tolerated, but it costs more than oral regimens. The available oral regimens against P. carinii, including dapsone-pyrimethamine, are associated with a high rate of discontinuation because of side effects, and there is clearly a need for new, better-tolerated oral drugs. In addition to P. carinii pneumonia, toxoplasmosis must also be prevented in persons seropositive for T. gondii who have low CD4+ T-lymphocyte counts. Dapsone-pyrimethamine will be the preventive regimen of choice until better-tolerated regimens are proved effective.
Supported by a grant (ANRS 003) from the Agence Nationale de Recherches sur le SIDA and by grants from the Institut de Medecine et d'Epidemiologie Tropicale, Paris, and Laboratoires Roger Bellon, Neuilly-sur-Seine, with the participation of the Association de Recherche, de Communication, et d'Action pour le Traitement du SIDA and Le Cercle des Medecins, Paris.
We are indebted to Jean-Jacques Pocidalo, Pharm.D., Claude Bazin, M.D., Nadine Martin, M.D., Bernard Regnier, M.D., Bernard Dupuis, M.D., Charles Mayaud, M.D., Erik Oksenhendler, M.D., Muriel Vray, and Michel Wolff, M.D., for their expertise; to David Young for his assistance in the preparation of the manuscript; and to the patients who participated in the trial.
Source Information
From the Institut National de la Sante et de la Recherche Medicale, Unite 13, Paris (P.-M.G., R.L., Claude Gaudebout, P.J.); the Pharmacie (A.C.) and the Services des Maladies Infectieuses et Tropicales (R.O., A.G.S., Christiane Gaudebout, E.B., J.-P.C.), Hopital Bichat-Claude Bernard, Paris; the Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Paris (T.L.); and the Service de Medecine Interne, Clamart (F.B.) -- all in France.
Address reprint requests to Dr. Girard at INSERM, Unite 13, 190 Blvd. MacDonald, 75019 Paris, France.
The members of the PRIO (Prevention des Infections Opportunistes) Study Group are listed in the Appendix.
Appendix
In addition to the study authors, the following persons and institutions participated in the PRIO Study Group.
Hopital Bichat-Claude Bernard, Paris: H. Balloul, S. Bartczak, H. Bideault, O. Bouchaud, R. Bousquet, F. Camus, C. Carbon, P. Coulaud, P. De Truchis, A. Dia, S. Fegueux, S. Halimi, S. Kernbaum, G. Kerouani, A. Lepretre, S. Mas, C. Maslo, S. Matheron, F. Mignot, G. Moreau, C. Picard, M.-H. Prevot, M. Ruquet, C. Ruggieri, C. Samson, Y. Tolila, F. Vachon, and C. Voyer; Hopital Broussais, Paris: J. Gilquin, M. Kazatchkine, and L. Weiss; Hopital Cochin, Paris: D. Sicard; Hopital Hotel Dieu, Paris: J.M. Brechot, P. Poubeau, and J. Rochemaure; Hopital Lariboisiere, Paris: J. Cervoni and C. Caulin; Hopital Pasteur, Paris: B. Dupont and G. Pialoux; Hopital Pitie-Salpetriere, Paris: E. Dohin, M. Gentilini, G. Guermonprez, and C. Katlama; Hopital Saint Louis, Paris: V. Averous, J.M. Decazes, G. Kouchner, J. Modai, and J.M. Molina; Hopital Antoine Beclere, Clamart: A. Blanc, J.F. Delfraissy, J. Dormont, and J.L. Martin; Hopital Louis Mourier, Colombes: M. Bloch, C. Michon, A.M. Simonpoli, and P. Vinceneux; Hopital Jean Verdier, Montfermeil: V. Jeantils, M.C. Schneider, and M. Thomas; Hopital Delafontaine, Saint Denis: P. Babinet, M.A. Khuong, D. Mechali, and G. Walckenaer; Hopital Henri Mondor, Creteil: J.C. Benaym, P. Boudes, P. De Vlaemink, and A. Sobel; Centre Hospitalier Universitaire de Dijon: P. Chavanet, J.P. Kisterman, H. Portier, and A. Waldner; Centre Hospitalier Universitaire de Lyon: P. Boibieux, D. Peyramond, and G. Tempelhoff; Centre Hospitalier Universitaire de Montpellier: N. Fegueux and J.-M. Navarro; Centre Hospitalier Universitaire de Nice: E. Rosenthal and J.P. Cassuto; Centre Hospitalier Universitaire de Villeneuve-Saint-Georges: J.E. Malkin and C. Lafaix; and Institut National de la Sante et de la Recherche Medicale, Unite 13: J.J. Pocidalo.
- References
References
1
Murray JF ,Garay SM ,Hopewell PC ,Mills J ,Snider GL ,Stover DE . Pulmonary complications of the acquired immunodeficiency syndrome: an update: report of the second National Heart, Lung, and Blood Institute workshop. Am Rev Respir Dis 1987;135:504-509
Web of Science | Medline2
Selik RM ,Starcher ET ,Curran JW . Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1987;1:175-182
Web of Science | Medline3
Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus 4
Hughes WT ,Kuhn S ,Chaudhary S , et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977;297:1419-1426
Full Text | Web of Science | Medline5
Hughes WT ,Rivera GK ,Schell MJ ,Thornton D ,Lott L . Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987;316:1627-1632
Full Text | Web of Science | Medline6
Fischl MA ,Dickinson GM ,La Voie L . Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988;259:1185-1189
CrossRef | Web of Science | Medline7
Girard P-M ,Landman R ,Gaudebout C , et al. Prevention of Pneumocystis carinii pneumonia relapse by pentamidine aerosol in zidovudine-treated AIDS patients. Lancet 1989;1:1348-1353
CrossRef | Web of Science | Medline8
Leoung GS ,Feigal DW Jr ,Montgomery AB , et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia: the San Francisco Community Prophylaxis Trial. N Engl J Med 1990;323:769-775
Full Text | Web of Science | Medline9
Montaner JSG ,Lawson LM ,Gervais A , et al. Aerosol pentamidine for secondary prophylaxis of AIDS-related Pneumocystis carinii pneumonia: a randomized, placebo-controlled study. Ann Intern Med 1991;114:948-953
Web of Science | Medline10
Murphy RL ,Lavelle JP ,Allan JD , et al. Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: results of a blinded dose-comparison study using an ultrasonic nebulizer. Am J Med 1991;90:418-426
Web of Science | Medline11
Hirschel B ,Lazzarin A ,Chopard P , et al. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 1991;324:1079-1083
Full Text | Web of Science | Medline12
Schneider MME ,Hoepelman AIM ,Eeftinck Schattenkerk JKM , et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992;327:1836-1841
Full Text | Web of Science | Medline13
Hardy WD ,Feinberg J ,Finkelstein DM , et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992;327:1842-1848
Full Text | Web of Science | Medline14
Hughes WT ,Smith BL . Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother 1984;26:436-440
Web of Science | Medline15
Medina I ,Mills J ,Leoung G , et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990;323:776-782
Full Text | Web of Science | Medline16
Lucas CR ,Sandland AM ,Mijch A ,Simpson JM . Primary dapsone chemoprophylaxis for Pneumocystis carinii pneumonia in immunocompromised patients infected with the human immunodeficiency virus. Med J Aust 1989;151:30-33
Web of Science | Medline17
Kemper CA ,Tucker RM ,Lang OS , et al. Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex. AIDS 1990;4:1145-1148
CrossRef | Web of Science | Medline18
Hughes WT ,Kennedy W ,Dugdale M , et al. Prevention of Pneumocystis carinii pneumonitis in AIDS patients with weekly dapsone. Lancet 1990;336:1066-1066
CrossRef | Web of Science | Medline19
Martin MA ,Cox PH ,Beck K ,Styer CM ,Beall GN . A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Arch Intern Med 1992;152:523-528
CrossRef | Web of Science | Medline20
Clotet B ,Sirera G ,Romeu J , et al. Twice-weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis. AIDS 1991;5:601-602
CrossRef | Web of Science | Medline21
Mallolas J ,Zamora L ,Gatell JM ,Miro JM ,Soriano E . Low-dose co-trimoxazole, aerosolized pentamidine, or dapsone plus pyrimethamine for prevention of Pneumocystis carinii pneumonia. Lancet 1991;337:1162-1163
CrossRef | Web of Science | Medline22
Blum RN ,Miller LA ,Gaggini LC ,Cohn DL . Comparative trial of dapsone versus trimethoprim-sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr 1992;5:341-347
Web of Science | Medline23
Slavin MA ,Hoy JF ,Stewart K ,Pettinger MB ,Lucas CR ,Kent SJ . Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. AIDS 1992;6:1169-1174
CrossRef | Web of Science | Medline24
Schwartlander B ,Horsburgh CR Jr ,Hamouda O ,Skarabis H ,Koch MA . Changes in the spectrum of AIDS-defining conditions and decrease in CD4+ lymphocyte counts at AIDS manifestation in Germany from 1986 to 1991. AIDS 1992;6:413-420
CrossRef | Web of Science | Medline25
Surveillance du SIDA en France: situation au 31 Mars 1992Bull Epidemiol Hebd 1992;19:81-87
26
Grant IH ,Gold JWM ,Rosenblum M ,Niedzwiecki D ,Armstrong D . Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS. AIDS 1990;4:519-521
CrossRef | Web of Science | Medline27
Clumeck N . Some aspects of the epidemiology of toxoplasmosis and pneumocystosis in AIDS in Europe. Eur J Clin Microbiol Infect Dis 1991;10:177-178
CrossRef | Web of Science | Medline28
Derouin F ,Beauvais B ,Lariviere M . Serological study of the prevalence of toxoplasmosis in 167 patients with acquired immunodeficiency syndrome (AIDS) or chronic lymphadenopathy syndrome (LAS). Biomed Pharmacother 1986;40:231-232
Web of Science | Medline29
Dannemann B ,McCutchan JA ,Israelski D , et al. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med 1992;116:33-43
Web of Science | Medline30
Jacobson MA ,Besch CL ,Child C , et al. Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Lancet 1992;339:333-334
CrossRef | Web of Science | Medline31
Allegra CJ ,Boarman D ,Kovacs JA , et al. Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase. J Clin Invest 1990;85:371-379
CrossRef | Web of Science | Medline32
Beverley JKA ,Fry BA . Sulphadimidine, pyrimethamine and dapsone in the treatment of toxoplasmosis in mice. Br J Pharmacol Chemother 1957;12:189-193
Web of Science | Medline33
Derouin F ,Piketty C ,Chastang C ,Chau F ,Rouveix B ,Pocidalo JJ . Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine. Antimicrob Agents Chemother 1991;35:252-255
Web of Science | Medline34
Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infectionsMMWR Morb Mortal Wkly Rep 1986;35:334-339
Medline35
Tschirhart D ,Klatt EC . Disseminated toxoplasmosis in the acquired immunodeficiency syndrome. Arch Pathol Lab Med 1988;112:1237-1241
Web of Science | Medline36
Holland GN ,Engstrom RE Jr ,Glasgow BJ , et al. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1988;106:653-667
Web of Science | Medline37
Pomeroy C ,Filice GA . Pulmonary toxoplasmosis: a review. Clin Infect Dis 1992;14:863-870
CrossRef | Web of Science | Medline38
Matheron S, Dournon E, Gharakhanian S, Leport C, Detruchis P, Gaudebout C. Prevalence of toxoplasmosis in 365 AIDS and ARC patients before and during zidovudine treatment. In: Abstracts of the Sixth International Conference on AIDS, San Francisco, June 20-24, 1990. Vol. 1. San Francisco: University of California, 1990:241. abstract.
39
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22040
O'Brien PC ,Fleming TR . A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556
CrossRef | Web of Science | Medline41
Phair J ,Munoz A ,Detels R , et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990;322:161-165
Full Text | Web of Science | Medline42
Ognibene AJ . Agranulocytosis due to dapsone. Ann Intern Med 1970;72:521-524
Web of Science | Medline43
Bruce-Chwatt LJ ,Hutchinson DBA . Agranulocytosis associated with Maloprim. BMJ 1984;288:65-66
CrossRef | Web of Science | Medline44
Jules-Elysee KM ,Stover DE ,Zaman MB ,Bernard EM ,White DA . Aerosolized pentamidine: effect on diagnosis and presentation of Pneumocystis carinii pneumonia. Ann Intern Med 1990;112:750-757
Web of Science | Medline45
Raviglione MC . Extrapulmonary pneumocystosis: the first 50 cases. Rev Infect Dis 1990;12:1127-1138
CrossRef | Medline46
Mycobacterium tuberculosis transmission in a health clinic -- Florida, 1988MMWR Morb Mortal Wkly Rep 1989;38:256-8, 263
Medline47
Horowitz HW ,Jorde UP ,Wormser GP . Drug interactions in use of dapsone for Pneumocystis carinii prophylaxis. Lancet 1992;339:747-747
CrossRef | Web of Science | Medline48
Metroka CE ,McMechan MF ,Andrada R ,Laubenstein LJ ,Jacobus DP . Failure of prophylaxis with dapsone in patients taking dideoxyinosine. N Engl J Med 1991;325:737-737
Web of Science | Medline49
Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virusMMWR Morb Mortal Wkly Rep 1992;41:1-11
Medline50
Beaman MH ,Luft BJ ,Remington JS . Prophylaxis for toxoplasmosis in AIDS. Ann Intern Med 1992;117:163-164
Web of Science | Medline51
Carr A ,Tindall B ,Brew BJ , et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992;117:106-111
Web of Science | Medline52
Heald A ,Flepp M ,Chave J-P , et al. Treatment for cerebral toxoplasmosis protects against Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med 1991;115:760-763
Web of Science | Medline53
Powderly WG ,Saag MS ,Cloud GA , et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:793-798
Full Text | Web of Science | Medline
- Citing Articles (45)
Citing Articles
1
Bogusław Buszewski, Paweł Olszowy, Małgorzata Szultka, Anna Jeżewska. (2012) New approaches to extraction techniques in determination of 4,4′-methylenebis(2-chloroaniline) in air and water solutions. Talanta
CrossRef2
Patricia Muñoz, Maricela Valerio, Alia Eworo, Emilio Bouza. (2011) Parasitic infections in solid-organ transplant recipients. Current Opinion in Organ Transplantation 16:6, 565-575
CrossRef3
Alison Green, Nathan Milne, Beng Beng Ong. (2011) Fatal bilateral pneumothoraces following administration of aerosolised pentamidine. Journal of Forensic and Legal Medicine 18:7, 332-335
CrossRef4
M Nelson, H Manji, E Wilkins. (2011) 2 Central nervous system opportunistic infections. HIV Medicine 12, 8-24
CrossRef5
Michael D. April, John J. Chiosi, A. David Paltiel, Paul E. Sax, Rochelle P. Walensky. (2011) Projected Survival Gains from Revising State Laws Requiring Written Opt-in Consent for HIV Testing. Journal of General Internal Medicine 26:6, 661-667
CrossRef6
HE Hsu, CE Rydzak, KL Cotich, B Wang, PE Sax, E Losina, KA Freedberg, SJ Goldie, Z Lu, RP Walensky, . (2011) Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Medicine 12:2, 97-108
CrossRef7
Jennifer Le, Elizabeth Dodds Ashley, Melinda M Neuhauser, Jack Brown, Chris Gentry, Michael E Klepser, Ann Marie Marr, Daryl Schiller, Joshua N Schwiesow, Sally Tice, Heather L VandenBussche, G. Christopher Wood. (2010) Consensus Summary of Aerosolized Antimicrobial Agents: Application of Guideline Criteria. Pharmacotherapy 30:6, 562-584
CrossRef8
Patricia Muñoz, Maricela Valerio, Daniel Puga, Emilio Bouza. (2010) Parasitic Infections in Solid Organ Transplant Recipients. Infectious Disease Clinics of North America 24:2, 461-495
CrossRef9
P. H. L. LAMBERTON, C. A. DONNELLY, J. P. WEBSTER. (2008) Specificity of the Toxoplasma gondii-altered behaviour to definitive versus non-definitive host predation risk. Parasitology 135:10,
CrossRef10
Luis M. Veggi, Luciana Pretto, Elena J. Ochoa, Viviana A. Catania, Marcelo G. Luquita, Diego R. Taborda, Enrique J. Sánchez Pozzi, Shin-ichi Ikushiro, Michael D. Coleman, Marcelo G. Roma, Aldo D. Mottino. (2008) Dapsone induces oxidative stress and impairs antioxidant defenses in rat liver. Life Sciences 83:5-6, 155-163
CrossRef11
Carlos S. Subauste, Jose G. Montoya, Jack S. Remington. 2008. AIDS-associated Toxoplasmosis. , 399-413.
CrossRef12
J.P Webster, P.H.L Lamberton, C.A Donnelly, E.F Torrey. (2006) Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour. Proceedings of the Royal Society B: Biological Sciences 273:1589, 1023-1030
CrossRef13
Andrew L. Campbell, Cindy L. Goldberg, Margret S. Magid, Gabriel Gondolesi, Carolina Rumbo, Betsy C. Herold. (2006) First Case of Toxoplasmosis Following Small Bowel Transplantation and Systematic Review of Tissue-Invasive Toxoplasmosis Following Noncardiac Solid Organ Transplantation. Transplantation 81:3, 408-417
CrossRef14
Andrea Antinori, Dora Larussa, Antonella Cingolani, Patrizia Lorenzini, Simona Bossolasco, Maria Grazia Finazzi, Marco Bongiovanni, Giovanni Guaraldi, Susanna Grisetti, Beniamino Vigo, Beniamino Gigli, Andrea Mariano, Ernesto Renato Dalle Nogare, Michele De Marco, Francesca Moretti, Paola Corsi, Nicola Abrescia, Patrizia Rellecati, Antonella Castagna, Cristina Mussini, Adriana Ammassari, Paola Cinque, Antonella d’Arminio Monforte, . (2004) Prevalence, Associated Factors, and Prognostic Determinants of AIDS‐Related Toxoplasmic Encephalitis in the Era of Advanced Highly Active Antiretroviral Therapy. Clinical Infectious Diseases 39:11, 1681-1691
CrossRef15
Rafik Samuel, Robert L. Bettiker, Byungse Suh. (2002) AIDS related opportunistic infections, going but not gone. Archives of Pharmacal Research 25:3, 215-228
CrossRef16
A. Gregory DiRienzo, Charles van der Horst, Dianne M. Finkelstein, Peter Frame, Samuel A. Bozzette, Karen T. Tashima. (2002) Efficacy of Trimethoprim–Sulfamethoxazole for the Prevention of Bacterial Infections in a Randomized Prophylaxis Trial of Patients with Advanced HIV Infection. AIDS Research and Human Retroviruses 18:2, 89-94
CrossRef17
Lotje H. Bosch-Driessen, Marjolijn B. Plaisier, Jan S. Stilma, Allegonda Van der Lelij, Aniki Rothova. (2002) Reactivations of ocular toxoplasmosis after cataract extraction. Ophthalmology 109:1, 41-45
CrossRef18
D. Schürmann, F. Bergmann, H. Albrecht, J. Padberg, T. Grünewald, M. Behnsch, M. Grobusch, M. Vallée, T. Wünsche, B. Ruf, N. Suttorp. (2001) Twice-weekly Pyrimethamine–sulfadoxine Effectively Prevents Pneumocystis carinii Pneumonia Relapse and Toxoplasmic Encephalitis in Patients with AIDS. Journal of Infection 42:1, 8-15
CrossRef19
Benjamin J. Luft, Arlene Chua. (2000) Central nervous system toxoplasmosis in HIV pathogenesis, diagnosis, and therapy. Current Infectious Disease Reports 2:4, 358-362
CrossRef20
Wood, Alastair J.J., , Kovacs, Joseph A., Masur, Henry, . (2000) Prophylaxis against Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection. New England Journal of Medicine 342:19, 1416-1429
Full Text21
Michoel W Dunne, Samuel Bozzetie, J Alen McCutchan, Michael P Dubé, Fred R Sattler, Donald Forthal, Carol Akemper, Diane Havlir. (1999) Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. The Lancet 354:9182, 891-895
CrossRef22
Adriana Ammassari, Giancarlo Scoppettuolo, Rita Murri, Patrizio Pezzotti, Antonella Cingolani, Cosmo Del Borgo, Andrea De Luca, Andrea Antinori, Luigi Ortona. (1998) Changing Disease Patterns in Focal Brain Lesion-Causing Disorders in AIDS. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 18:4, 365-371
CrossRef23
Matthew K. Wynia, John P.A. Ioannidis, Joseph Lau. (1998) Analysis of life-long strategies to prevent Pneumocystis carinii pneumonia in patients with variable HIV progression rates. AIDS 12:11, 1317-1325
CrossRef24
Heiner C. Bucher, Gordon H. Guyatt, Lauren E. Griffith, Stephen D. Walter. (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 50:6, 683-691
CrossRef25
Heiner C. Bucher, Lauren Griffith, Gordon H. Guyatt, Milos Opravil. (1997) Meta-Analysis of Prophylactic Treatments Against Pneumocystis carinii Pneumonia and Toxoplasma Encephalitis in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 15:2, 104-114
CrossRef26
Simon H.L. Thomas, Christopher J. Page, Philip J. Blower, Philip Chowienczyk, Alan Ward, Farhad Kamali, Caroline S. Bradbeer, Nigel T. Bateman, Michael J. O'Doherty. (1997) Disposition of intravenous 123iodopentamidine in man. Nuclear Medicine and Biology 24:4, 327-332
CrossRef27
François Raffi, Jean-Pierre Aboulker, Christian Michelet, Véronique Reliquet, Hervé Pelloux, Alain Huart, Isabelle Poizot-Martin, Philippe Morlat, Benoît Dupas, Jean-Marie Mussini, Catherine Leport. (1997) A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients. AIDS 11:2, 177-184
CrossRef28
Joanne M. Kelso, Cheng-Long Bai, Jorma T. Ahokas, Paul F.A. Wright. (1997) In vitro effects of MOCA and dapsone on rat hepatic and splenic immune cells. Immunopharmacology 35:3, 183-193
CrossRef29
Hugo M. Weigel, Erwin De Vries, Rosa M. Regez, Jeanette H. Henrichs, Jos J. A. M. Ten Velden, P. H. Jos Frissen, Jan T. M. Van Der Meer. (1997) Cotrimoxazole is Effective as Primary Prophylaxis for Toxoplasmic Encephalitis in HIV-infected Patients: A Case Control Study. Scandinavian Journal of Infectious Diseases 29:5, 499-502
CrossRef30
Stewart J. Levine. (1996) PNEUMOCYSTIS CARINII. Clinics in Chest Medicine 17:4, 665-695
CrossRef31
Horatio B. Fung, Harold L. Kirschenbaum. (1996) Treatment regimens for patients with toxoplasmic encephalitis. Clinical Therapeutics 18:6, 1037-1056
CrossRef32
JEAN-LOUIS POIROT, MARIE MARTEAU, ISABELLE LAVRARD, MARIE-CAROLINE MEYOHAS, JACQUES CADRANEL, PATRICIA ROUX. (1996) Praeumocystis carinii Pneumonia: Evolution from 1981 to 1995 in Two Paris Hospitals.. The Journal of Eukaryotic Microbiology 43:5, 58S-59S
CrossRef33
M. Cruciani, E. Bertazzoni Minelli, M. Mirandola, R. Luzzati, M. Merighi, L. Lazzarini, G. Gatti, S. Vento, R. Mazzi, M. Malena, A. Benini, A. Cazzadori, G. Piemonte, D. Bassetti, E. Concia. (1996) Twice-weekly dapsone for primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infection: efficacy, safety and pharmacokinetic data. Clinical Microbiology and Infection 2:1, 30-35
CrossRef34
Gerald J. Dal Pan, Justin C. McArthur. (1996) NEUROEPIDEMIOLOGY OF HIV INFECTION. Neurologic Clinics 14:2, 359-382
CrossRef35
G.P. Rizzardi, A. Lazzarin, M. Musicco, D. Frigerio, M. Maillard, M. Lucchini, M. Moroni. (1996) Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial. Journal of Infection 32:2, 123-131
CrossRef36
Josiah D. Rich, Mark Mirochnick. (1996) Dapsone penetrates cerebrospinal fluid during Pneumocystis carinii pneumonia prophylaxis. Diagnostic Microbiology and Infectious Disease 24:2, 77-79
CrossRef37
M. F. Letillois, V. Laigle, F. Santoro, M. Micoud, B. F. F. Chumpitazi. (1995) Toxoplasma gondii surface antigen-1 in sera of HIV-infected patients as an indicator of reactivated toxoplasmosis. European Journal of Clinical Microbiology & Infectious Diseases 14:10, 899-903
CrossRef38
A. E. Jolley, J. G. M. Hastings. (1995) Therapeutic progress IV: Treatment and prophylaxis of Pneumocystis carinii infection. Journal of Clinical Pharmacy and Therapeutics 20:3, 121-130
CrossRef39
Clumeck, Nathan, . (1995) Primary Prophylaxis against Opportunistic Infections in Patients with AIDS. New England Journal of Medicine 332:11, 739-740
Full Text40
Bozzette, Samuel A., Finkelstein, Dianne M., Spector, Stephen A., Frame, Peter, Powderly, William G., He, Weili, Phillips, Lucinda, Craven, Donald, van der Horst, Charles, Feinberg, Judith, . (1995) A Randomized Trial of Three Antipneumocystis Agents in Patients with Advanced Human Immunodeficiency Virus Infection. New England Journal of Medicine 332:11, 693-699
Full Text41
V.J. Quagliarello, C. Viscoli, R.I. Horwitz. (1995) Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients. The Lancet 345:8949, 548-552
CrossRef42
L.E. Rhodes, M.D. Tingle, B.K. Park, P. Chu, J.L. Verbov, P.S. Friedmann. (1995) Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. British Journal of Dermatology 132:2, 257-262
CrossRef43
John G. Guccion, Debra A. Benator, Cynthia L. Gibert, Harish P. G. Dave. (1995) Disseminated Toxoplasmosis and Acquired Immunodeficiency Syndrome: Diagnosis by Transmission Electron Microscopy. Ultrastructural Pathology 19:2, 95-99
CrossRef44
C. Benichou, M. Eliaszewicz, A. Flahault. (1994) Adverse drug reactions in HIV seropositive patients. Pharmacoepidemiology & Drug Safety 3:1, 31-40
CrossRef45
Hoover, Donald R.Saah, Alfred J.Bacellar, HelenaPhair, JohnDetels, RogerAnderson, RogerKaslow, Richard A.. (1993) Clinical Manifestations of AIDS in the Era of Pneumocystis Prophylaxis. New England Journal of Medicine 329:26, 1922-1926
Full Text
